We also showed that the miR-494/G6pc axis promotes sorafenib resistance and proposed combining antagomiR-based treatments with sorafenib or 2-deoxyglucose (2-DG) for HCC patients who may develop sorafenib resistance and who are ineligible for immunotherapy [68]. Here, G6PC1 is linked to hepatocellular carcinoma.